Logo image of LIMN

LIMINATUS PHARMA INC-CL A (LIMN) Stock Fundamental Analysis

USA - NASDAQ:LIMN - US53271X1081 - Common Stock

1.04 USD
-0.03 (-2.8%)
Last: 11/17/2025, 2:58:23 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to LIMN. LIMN was compared to 533 industry peers in the Biotechnology industry. LIMN has a bad profitability rating. Also its financial health evaluation is rather negative. LIMN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LIMN had negative earnings in the past year.
In the past year LIMN has reported a negative cash flow from operations.
In multiple years LIMN reported negative net income over the last 5 years.
LIMN had a negative operating cash flow in each of the past 5 years.
LIMN Yearly Net Income VS EBIT VS OCF VS FCFLIMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M 6M 8M 10M

1.2 Ratios

LIMN's Return On Assets of -102.67% is on the low side compared to the rest of the industry. LIMN is outperformed by 75.80% of its industry peers.
Industry RankSector Rank
ROA -102.67%
ROE N/A
ROIC N/A
ROA(3y)-21.24%
ROA(5y)-12.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LIMN Yearly ROA, ROE, ROICLIMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LIMN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIMN Yearly Profit, Operating, Gross MarginsLIMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, LIMN has less shares outstanding
The debt/assets ratio for LIMN is higher compared to a year ago.
LIMN Yearly Shares OutstandingLIMN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LIMN Yearly Total Debt VS Total AssetsLIMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -14.55, we must say that LIMN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -14.55, LIMN is not doing good in the industry: 78.80% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.55
ROIC/WACCN/A
WACCN/A
LIMN Yearly LT Debt VS Equity VS FCFLIMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

LIMN has a Current Ratio of 0.09. This is a bad value and indicates that LIMN is not financially healthy enough and could expect problems in meeting its short term obligations.
LIMN has a Current ratio of 0.09. This is amonst the worse of the industry: LIMN underperforms 97.19% of its industry peers.
LIMN has a Quick Ratio of 0.09. This is a bad value and indicates that LIMN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.09, LIMN is doing worse than 97.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
LIMN Yearly Current Assets VS Current LiabilitesLIMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

LIMN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -158.02%.
EPS 1Y (TTM)-158.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LIMN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIMN Price Earnings VS Forward Price EarningsLIMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIMN Per share dataLIMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LIMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIMINATUS PHARMA INC-CL A

NASDAQ:LIMN (11/17/2025, 2:58:23 PM)

1.04

-0.03 (-2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-06 2025-10-06
Earnings (Next)N/A N/A
Inst Owners0.76%
Inst Owner Change27.95%
Ins OwnersN/A
Ins Owner Change0%
Market Cap28.14M
Revenue(TTM)N/A
Net Income(TTM)-2.90M
AnalystsN/A
Price TargetN/A
Short Float %4.97%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS-0.59
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -102.67%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.24%
ROA(5y)-12.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z -14.55
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-158.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.61%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.69%
OCF growth 3YN/A
OCF growth 5YN/A

LIMINATUS PHARMA INC-CL A / LIMN FAQ

What is the ChartMill fundamental rating of LIMINATUS PHARMA INC-CL A (LIMN) stock?

ChartMill assigns a fundamental rating of 0 / 10 to LIMN.


What is the valuation status for LIMN stock?

ChartMill assigns a valuation rating of 0 / 10 to LIMINATUS PHARMA INC-CL A (LIMN). This can be considered as Overvalued.


What is the profitability of LIMN stock?

LIMINATUS PHARMA INC-CL A (LIMN) has a profitability rating of 0 / 10.


Can you provide the financial health for LIMN stock?

The financial health rating of LIMINATUS PHARMA INC-CL A (LIMN) is 0 / 10.